A combination of economic and regulatory factors are driving up the cost and complexity of biopharma supply chains in the EU. This paper explores those factors and outlines both “upstream” and “downstream” strategies that pharma and biotech companies can use to better manage cost, complexity, and risk.
Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common. However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.
On October 20, 2022, AIM conducted a webinar on how companies can orchestrate successful supply chains for ATMPs. This paper provides a written summary of the webinar discussion.
For a time, webinar registrants can also access a recorded copy of the webinar here.
On 27 October 2021, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.
Our panel of experts included:
- Pim Van Der Aar, Co-Founder & Managing Director, AIM (Moderator)
- Christian Ellereit, Head of Finance, Europe, Travere Therapeutics
- Ronald van Zitteren, Principal, AIM
- Joop Wijdeven, Associate, AIM
The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.